Home About us Contact
|
Home About us Contact | ||
|
|
||
Seborrheic Dermatitis (seborrheic + dermatitis)
Selected AbstractsCiclopirox 1% shampoo for the treatment of seborrheic dermatitisINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 1 2006Aditya K. Gupta MD, FRCP(C) Seborrheic dermatitis is a chronic superficial fungal infection of the skin, particularly affecting sites rich in sebaceous glands. Although the precise etiology of seborrheic dermatitis is uncertain, yeasts of the genus Malassezia are known to play a causative role. Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent, which also has anti-inflammatory properties. Ciclopirox is effective both in vitro and in vivo against Malassezia yeasts, making it a valuable option for the treatment of seborrheic dermatitis. Varying frequencies and concentrations of ciclopirox shampoo have been shown to be effective and safe in the treatment of seborrheic dermatitis of the scalp. [source] The differential diagnosis of atopic dermatitis in childhoodDERMATOLOGIC THERAPY, Issue 2 2006Alfons Krol ABSTRACT:, Atopic is the most common of the dermatitides seen in infancy and childhood, but there are numerous other diseases that can mimic the skin findings. These include seborrheic dermatitis, immunodeficiency, and psoriasis in infancy; scabies, tinea corporis infection, perioral, nummular, contact, and molluscum dermatitis in childhood. It is sometimes extremely difficult to differentiate between ichthyosis and AD, and it is also important to differentiate AD from erythrodermic conditions including acrodermatitis enteropathica, biotin deficiency, and Netherton syndrome. A rare condition in children that may mimic AD is mycosis fungoides. [source] Pimecrolimus in dermatology: atopic dermatitis and beyondINTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Issue 8 2005Paolo Gisondi Summary Pimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells. Pimecrolimus inhibits T-cell proliferation, as well as production and release of interleukin-2 (IL-2), IL-4, interferon-, and tumour necrosis factor-,. Moreover, pimecrolimus inhibits mast cell degranulation. In contrast to tacrolimus, pimecrolimus has no effects on the differentiation, maturation and functions of dendritic cells. In contrast to corticosteroids, pimecrolimus does not affect endothelial cells and fibroblasts and does not induce skin atrophy. Given the low capacity of pimecrolimus to permeate through the skin, it has a very low risk of systemic exposure and subsequent systemic side-effects. In different randomised controlled trials, topical pimecrolimus as cream 1% (Elidel®) has been shown to be effective, well tolerated and safe in both adults and children with mild to moderate AD. In addition, pimecrolimus has been successfully used in inflammatory skin diseases other than AD, including seborrheic dermatitis, intertriginous psoriasis, lichen planus and cutaneous lupus erythematosus. [source] A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activityINTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Issue 4 2003P. Bailey Synopsis Dandruff is a common problem in approximately 30% of the world's population. Reports in the literature regarding treatment of this condition with various antidandruff shampoos usually report the level of active ingredient within the formulation. However, we propose that a more important parameter relating to antidandruff efficacy is the amount of active ingredient delivered to the scalp from the shampoo. This report describes the results from two studies designed to investigate the relationship between the level of zinc pyrithione (ZnPTO) deposited onto the scalp and the resultant scalp condition. A double-blind randomized vehicle-controlled clinical study comparing three shampoos , a vehicle, a low-depositing ZnPTO shampoo and a high-depositing ZnPTO shampoo , was carried out in the U.K. with 53 panelists with dandruff or mild-to-moderate seborrheic dermatitis of the scalp. Both shampoos containing ZnPTO were significantly superior in antidandruff efficacy to the vehicle. Furthermore, the high-depositing ZnPTO shampoo was significantly superior compared with the low-depositing ZnPTO shampoo in terms of both antidandruff efficacy and antimycotic activity. Antidandruff performance and antimycotic activity of ZnPTO-containing shampoos is highly dependent on the amount of active ingredient delivered to the scalp. Furthermore, careful manipulation of the formulation parameters of an antidandruff shampoo can result in enhanced levels of delivery of the active ingredient without having to increase the level of active ingredient within the formulation. Résumé Les pellicules sont un problème courant rencontré par environ 30% de la population mondiale. Les rapports de la littérature relatifs à son traitement par des shampooings antipelliculaires mentionnent couramment le taux d'actif inclus dans la formule. Nous proposons cependant un paramètre plus important, vis à vis de l'activité antipelliculaire, c'est à dire le taux d'actif délivré par le shampooing sur le cuir chevelu. Cet article décrit les résultats de deux études conçues pour déterminer les types de relation entre le taux de Zn PTO déposé sur le cuir chevelu et l'état de celui ci qui en résulte. Une étude randomisée, contrôlée par véhicule, a comparé 3 shampooings (la base véhicule non traitante, un shampooing à faible déposition de Zn PTO et un shampooing à fort taux de dépôt de Zn PTO), a été conduite au Royaume Uni sur 53 volontaires sujets pelliculaires ou à faible ou modérée Dermite Séborrhéique. Les deux shampooings contenant le Zn PTO ont été trouvés significativement supérieurs dans leur activité anti pelliculaire au véhicule. De plus, le shampooing à fort dépôt était significativement plus efficace que celui à faible dépôt, tant dans l'activité anti pellicualire qu'anti mycotique. En conclusion, la performance anti pelliculaire et anti mycotique de shampooings à base de Zn PTO semble hautement dépendante du taux d'actif délivré sur le cuir chevelu. De plus, un choix judicieux des paramètres de formulation du shampooing anti pelliculaire peut amener à accroître les taux de délivrance de l'actif sans avoir à augmenter celui ci au sein de la formule. [source] Ciclopirox 1% shampoo for the treatment of seborrheic dermatitisINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 1 2006Aditya K. Gupta MD, FRCP(C) Seborrheic dermatitis is a chronic superficial fungal infection of the skin, particularly affecting sites rich in sebaceous glands. Although the precise etiology of seborrheic dermatitis is uncertain, yeasts of the genus Malassezia are known to play a causative role. Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent, which also has anti-inflammatory properties. Ciclopirox is effective both in vitro and in vivo against Malassezia yeasts, making it a valuable option for the treatment of seborrheic dermatitis. Varying frequencies and concentrations of ciclopirox shampoo have been shown to be effective and safe in the treatment of seborrheic dermatitis of the scalp. [source] Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitisINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue S1 2004Aditya K. Gupta MD, FRCP(C) No abstract is available for this article. [source] Itraconazole in the treatment of seborrheic dermatitis: a new treatment modalityINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 1 2004Vahide Baysal MD Background, Due to the high rate of recurrence, seborrheic dermatitis (SD) represents a therapeutic problem. Aim, To evaluate the role of oral itraconazole in the treatment of SD. Patients and methods, Thirty-two patients with SD were enrolled in the study. All topical and oral treatments were stopped. The patients applied 1% hydrocortisone cream twice daily for 1 month. In addition, they took itraconazole, 200 mg/day, during the first week of the first month and then hydrocortisone cream was stopped and itraconazole (200 mg/day) was given on the first 2 days of the following 11 months. The patients were followed for 2 months without medicine. The severity score was measured at the initial evaluation, and at the first, 12th, and 14th months. Results, Twenty-eight patients completed the study. There was a statistically significant decrease in the mean severity score at the first, 12th, and 14th months. On the final evaluation at the 12th month, 19 of the 28 patients showed a complete improvement, and three patients showed a slight improvement. Conclusions, This study indicates that itraconazole plays an important role in the treatment of SD. [source] Ciclopirox for the treatment of superficial fungal infections: a reviewINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue S1 2003Aditya K. Gupta MD, F.R.C.P.(C) Ciclopirox is a broad-spectrum antifungal agent that also exhibits anti-inflammatory and antibacterial activity. The lotion and cream formulations of ciclopirox are effective in many types of infection, including tinea corporis/cruris, tinea pedis, cutaneous candidiasis, pityriasis (tinea) versicolor, and seborrheic dermatitis. The new ciclopirox gel 0.77% formulation is also indicated for the treatment of seborrheic dermatitis of the scalp, interdigital tinea pedis and tinea corporis. [source] Oral terbinafine for the treatment of seborrheic dermatitis in adultsINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 11 2002Nicoletta Cassano MD No abstract is available for this article. [source] The Spectrum of Skin Disease Among Indian ChildrenPEDIATRIC DERMATOLOGY, Issue 1 2009D.N.B., Kabir Sardana M.D., M.N.A.M.S. A retrospective study was designed to evaluate the epidemiologic features of pediatric dermatoses in India. The setting was a tertiary care referral center in India (Kalawati Saran Children's Hospital, New Delhi) during January 1997 to December 2003. A total of 30,078 children less than 12 years of age with 32,341 new dermatoses were recorded, with a male to female ratio of 1.07:1. Most of the disease was seen in the 1- to 5-year age group (44.94%). The most common skin diseases were infections and infestations (47.15%) consisting of bacterial infections (58.09%) and scabies (21.54%), followed by eczemas (26.95%), infantile seborrheic dermatitis, scabies, and pityriasis alba. Other unique dermatoses in our settings were papular uticaria (3.59%), miliaria (5.46%), postinflammatory pigmentary abnormalities (1.68%), and nutritional deficiency dermatoses (0.45%). A majority of patients were diagnosed clinically and special diagnostic tests were conducted in 2.6% of patients. The most common diagnostic test used was KOH mount (59.2%), followed by skin biopsy (39%). Nearly 90% of patients were seen without any referral and in the remaining, a majority were referred by pediatricians (75%). A majority of patients were diagnosed to have infection followed by dermatitis in our setting. [source] Antifungal activity of the aqueous extract of Ilex paraguariensis against Malassezia furfurPHYTOTHERAPY RESEARCH, Issue 5 2010Rosana Filip Abstract Malassezia furfur is a lipodependent, dimorphic and saprophyte fungus which causes pityriasis versicolor, dandruff and seborrheic dermatitis in humans. The drugs available to treat this fungal infection are few. These drugs are highly toxic and are costly when used in prolonged treatments. For these reasons, it is necessary to find new compounds to treat these infections. Ilex paraguariensis St Hilaire is a plant that grows in Argentina, Brazil and Paraguay. The aim of this study was to evaluate the effect of the aqueous extract of Ilex paraguariensis on the growth of M. furfur. High performance liquid chromatography (HPLC) was employed to identify and isolate compounds of I. paraguariensis and the agar-well diffusion method was used to assess the antifungal activity of the extract. The fungicidal/fungistatic effect was evaluated by the modified Thompson assay. The results demonstrated that the aqueous extract of Ilex paraguariensis (1000,mg/ml) possesses inhibitory activity against M. furfur. This antimalassezial activity was equivalent to 2.7,,g/ml of ketoconazole. Therefore, the topical use of Ilex paraguariensis extract as alternative antifungal agent can be suggested. Copyright © 2009 John Wiley & Sons, Ltd. [source] Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: A comparative studyTHE JOURNAL OF DERMATOLOGY, Issue 3 2009Hyoseung SHIN ABSTRACT Previous studies have shown that topical steroid and shampoo containing zinc pyrithione provide clinical benefits for treatment of scalp seborrheic dermatitis. But the clinical efficacy of topical tacrolimus, a newly developed calcineurin inhibitor on seborrheic dermatitis, is not well investigated yet. We wanted to compare the clinical efficacy of topical tacrolimus with that of conventional treatment (zinc pyrithione shampoo and topical betamethasone) for treatment of seborrheic dermatitis of the scalp. Patients with seborrheic dermatitis of the scalp were randomly allocated to receive topical betamethasone, topical tacrolimus or zinc pyrithione shampoo. Some patients were instructed to continue the treatments for 8 weeks and the others to discontinue the treatments at week 4. We evaluated the efficacy using a clinical severity score, dandruff score and sebum secretion at baseline, week 4 and week 8. All treatment groups showed significant improvements in clinical assessment after 4 weeks. While the patients treated by zinc pyrithione improved continuously even after cessation of the treatment, the patients treated by betamethasone lotion or tacrolimus ointment were aggravated clinically. Topical tacrolimus was as effective as topical betamethasone, and showed more prolonged remission than topical betamethasone. To treat seborrheic dermatitis of the scalp, we think that the combination therapy of topical steroid or topical tacrolimus, and zinc pyrithione is recommended. [source] Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescentsTHE JOURNAL OF DERMATOLOGY, Issue 9 2008Hong ZHANG ABSTRACT Sebaceous gland diseases are a group of common dermatological diseases with multiple causes. To date, a systematic report of the risk factors for sebaceous gland diseases in adolescents has not been published. The aim of this study was to assess the prevalence and risk factors for certain sebaceous gland diseases (seborrhea, seborrheic dermatitis, acne, androgenetic alopecia and rosacea) and their relationship to gastrointestinal dysfunction in adolescents. From August,October, 2002,2005, a questionnaire survey was carried out to obtain epidemiological data about sebaceous gland diseases. Using random cluster sampling, 13 215 Han adolescents aged 12,20 years were recruited from four countries or districts (Macau; Guangzhou, China; Malaysia; and Indonesia). The statistical software SPSS ver. 13.0 was used to analyze the data. The prevalence of seborrhea, seborrheic dermatitis, acne, androgenetic alopecia and rosacea was 28.27%, 10.17%, 51.03%, 1.65% and 0.97%, respectively. Based on multivariate logistic regression analysis, the risk factors for sebaceous gland diseases included: age; duration of local residency; halitosis; gastric reflux; abdominal bloating; constipation; sweet food; spicy food; family history of acne; late night sleeping on a daily basis; excessive axillary, body and facial hair; excessive periareolar hair; and anxiety. There was a statistically significant difference in the prevalence of gastrointestinal symptoms (halitosis; gastric reflux; abdominal bloating; constipation) between patients with and without sebaceous gland diseases (,2 = 150.743; P = 0.000). Gastrointestinal dysfunction is an important risk factor for diseases of the sebaceous glands and is correlated with their occurrence and development. [source] | ||||||||||